Global Huntington’s Disease Treatment Market Forecast Report by Drug Type (Approved Drugs, Off-label Drugs) End user (Hospital Pharmacy, Drug Store & Retail Pharmacy, Online Pharmacy) Countries and Company Analysis, 2024-2032

Global Huntington’s Disease Treatment Market Forecast Report by Drug Type (Approved Drugs, Off-label Drugs) End user (Hospital Pharmacy, Drug Store & Retail Pharmacy, Online Pharmacy) Countries and Company Analysis, 2024-2032

Huntington’s Disease Treatment Market Analysis

Global Huntington’s Disease Treatment Market is expected to grow beyond US$ 1,728.6 million in the year 2032, up from US$ 436.0 million in 2023, with a CAGR of 16.54 percent from 2024 to 2032. This growth has been driven by a rise in the cases of Huntington’s disease, the rise in need for more sophisticated approaches to managing the illness, and the innovations in newer treatment methods.

Huntington’s Disease Treatment Market Outlook

Huntington’s disease (HD) commonly known as hunt disease is a genetic neurological disorder that affects people’s motor control, thinking ability and psychiatric symptoms. This type of dementia usually develops during the middle age and is characterized by motor disorder, loss of cognitive abilities and psychiatric symptoms; major one being depression and anxiety. Fundamentally, it is resulted from mutation of the HTT gene and lead to abnormally formed huntingtin protein, which leads to the substantia’s deposit in brain cells, thus causing their death.

Huntington’s disease treatment mainly centers on preventing further complications and providing comfort, as there is no known cure to the illness. Chorea is managed by rather specific drugs such as tetrabenazine and deutetrabenazine. There is a short treatment that employs the use of antipsychotic drugs and antidepressants to treat psychosis symptoms. Also, other anti-Alzheimer’s therapies including the gene therapies and stem cell research are being investigated with a view of arresting disease progression. Current research clinical trials are also assessing the possibilities of new drugs and treatments for changing the disease’s trajectory.

Growth Drivers of Huntington’s Disease Treatment

Rising prevalence of Huntington's disease globally

A growing rate of prevalence of Huntington’s disease across the globe is another factor that contribute to the market expansion. The consumption of medicines increases during earlier stages of the disease with increased outcome and awareness of the disease. Enhanced effectiveness of diagnosing procedures and genetic tests help in early diagnosis and management. It also emphasises the increasing health care demand that Huntington’s disease causes as well as encourages pharmaceutical innovation. Thus, the awareness of a growing number of sufferers who are looking for not only symptom relief but also therapy that can, directly or indirectly, influence the change of the disease course.

Research into Huntington's disease has yielded new therapeutic approaches

Recent research in Huntington’s disease patient has led to the discovery of new therapeutic interventions like gene therapies that seek to suppress the mutant huntingtin protein that is characteristic of this disease. Such innovations can be seen to proactively alter the disease management’s course and provide new forms of treatment. This benefit improves the care of patients and at the same time stimulates the development of the market through the appearance of new individualized and effective treatments. As these new therapies advance through the phases of clinical trials and approval the treatment for Huntington’s disease will be meeting the un- met need of the global market and thus fueling growth in this domain.

The expanding pharmaceutical pipeline dedicated to Huntington's disease treatments

The availability of pipeline molecules that are still in the early stages of development for Huntington’s disease will prove to be the driving force in the market progression. The market is still considered large and rewarding for such pharmaceutical companies, which, in turn, is encouraging them to invest more in their research and development divisions. All of the below-listed therapeutic pipelines include an appropriate mix of medicines for symptomatic management of Huntington’s disease such as chorea, deteriorated cognitive abilities, and other disease-modifying treatments that address the fundamental cause of Huntington’s disease. Thus, the further development of these therapies is promising in improving patients’ prognosis and acting on the well-being of those patients and their carers, who have many unmet needs. These novel therapies are to become available to patients after passing through phases of their trials and achieving regulatory stature to bring significant changes to the Huntington’s therapeutic market in the future.

Asia Huntington’s Disease Treatment Market

Huntington’s disease treatment market is also experiencing growth in Asia due to several factors. Rising consciousness and detection rates in densely populated nations like China, India and Japan positively affect the need for the market. These nations are building up healthcare facilities and concentrating on neurodegenerative disorder treatment and diagnosis, thereby increasing the need for efficient solution. High spending on research and-development coupled with the favorable governmental policies ensure that pharmacy companies devise better therapies suitable for the different parts. Moreover, increase in knowledge concerning genetics and diagnostics leads to better control of diseases and timely diagnosis of their symptoms. They could include the increasing costs in healthcare in advanced and developing nations as well as the increasing prevalence of chronic diseases; all are expected to increase the market of Huntington’s disease in the Asia-Pacific region. In this ever-shifting environment, local & global biopharmaceutical companies have the chance to meet patients’ abovementioned needs & enhance regional patient care.

Global Huntington’s Disease Treatment Company Analysis:

Some leading Huntington’s Disease Treatment companies are H Lundbeck, Pfizer Inc., Bausch Health Cos, Teva Pharmaceutical Industries, Dr Reddy's Laboratories, Sun Pharmaceutical Industries Limited, Hikma Pharmaceuticals Plc, Alnylam Pharmaceuticals, Novartis AG, UniQure.

Global Huntington’s Disease Treatment Company News:

October 2023: The US Food and Medication Administration (FDA) designated Sage Therapeutics' SAGE-718 as an orphan medication for treating Huntington's disease.

September 2023: The U.S. Food and Drug Administration (FDA) has approved Neurocrine Biosciences, Inc.'s New Drug Application (NDA) for INGREZZA oral granules, a novel sprinkle formulation.

August 2023: The US Food and Drug Administration (FDA) approved valbenazine, sold under the name INGREZZA, to treat these symptoms. Neurocrine Biosciences developed the drug.

April 2023: At the American Academy of Neurology (AAN) Annual Meeting, Prilenia Therapeutics B.V. presented the top-line results from the Phase 3 PROOF-HD clinical study, which looked at the efficacy and safety of pridopidine in people with Huntington's disease (HD).

Drug Type –Market Breakup in 2 Viewpoints –

1. Approved Drugs
2. Off-label Drugs

End Users – Market Breakup in 3 Viewpoints –

1. Hospital Pharmacy
2. Drug Store & Retail Pharmacy
3. Online Pharmacy

Geography – Market Breakup of 23 countries -

North America

o United States
o Canada

Europe

o France
o Germany
o Italy
o Spain
o United Kingdom
o Netherlands

Asia Pacific

o China
o Japan
o India
o Australia
o South Korea
o Malaysia
o Indonesia
o Israel

Latin America

o Brazil
o Mexico
o Argentina
o Colombia

Middle East & Africa

o South Africa
o Saudi Arabia
o UAE

Company Insights:

• Overview
• Recent Development
• Product Portfolio
• Revenue

Key Players Analysis:

1. H Lundbeck
2. Pfizer Inc.
3. Bausch Health Cos
4. Teva Pharmaceutical Industries
5. Dr Reddy's Laboratories
6. Sun Pharmaceutical Industries Limited
7. Hikma Pharmaceuticals Plc
8. Alnylam Pharmaceuticals
9. Novartis AG
10. UniQure